Literature DB >> 15925999

Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).

Martin Benesch1, Sabine Wagner, Frank Berthold, Johannes E A Wolff.   

Abstract

PURPOSE: Clinical data on central nervous system (CNS) dissemination of high-grade gliomas (HGG) at initial presentation in children are rare. PATIENTS AND METHODS: We conducted a retrospective data analysis of all patients enrolled into four consecutive HGG protocols of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH) to determine the incidence of primary CNS dissemination of HGG and to describe clinical characteristics and outcome of children with HGG who were diagnosed with CNS dissemination at initial presentation. 546 patients with newly diagnosed HGG (n=348) or diffuse intrinsic pontine gliomas (n=198) were enrolled in these four studies. Data concerning tumor dissemination are available from 324 patients.
RESULTS: A total of 10 patients (3.1%) (anaplastic astrocytoma: n=3, glioblastoma multiforme: n=6, diffuse intrinsic pontine glioma: n=1) had primary tumor dissemination. Median age at diagnosis was 9.3 years (range: 0.3-21.3 years). The most frequent primary tumor sites were the cortex (n=4), followed by the ventricles (n=2), cerebellum (n=1), spinal cord (n=1), and pons (n=1). One patient had diffuse gliomatosis cerebri. Following surgery eight patients received local radiotherapy and eight additional chemotherapy. At a median follow-up of 10 months (range: 0.05-3 years) four patients are alive. None is disease-free. Median progression-free and overall survival was 0.8 years (95% CI 0.2-1.4) and 1.5 years (95% CI 0.67-2.29) for patients with primary tumor dissemination, respectively, with no statistically significant differences between the group with and the group without primary tumor dissemination.
CONCLUSIONS: Initial diagnostic evaluation should include complete CNS imaging as well as cerebrospinal fluid examination in all patients with HGG. As prognosis of children with HGG and primary CNS dissemination was not inferior to patients without dissemination in our population, these patients should be treated in the same way as patients without primary CNS dissemination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925999     DOI: 10.1007/s11060-004-3546-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Supratentorial malignant gliomas in childhood: a review of fifty cases.

Authors:  E J Dropcho; J H Wisoff; R W Walker; J C Allen
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

2.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

3.  Malignant astrocytic gliomas in children.

Authors:  M J Marchese; C H Chang
Journal:  Cancer       Date:  1990-06-15       Impact factor: 6.860

4.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

5.  Leptomeningeal metastasis from supratentorial malignant gliomas.

Authors:  I Awad; J W Bay; L Rogers
Journal:  Neurosurgery       Date:  1986-08       Impact factor: 4.654

6.  Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a phase I study.

Authors:  Johannes E A Wolff; Sabine Wagner; Marina Sindichakis; Thorsten Pietsch; Astrid Gnekow; Rolf-Dieter Kortmann; Ronald Sträter; Joachim Kuehl
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

7.  Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in children.

Authors:  E D Kramer; S Rafto; R J Packer; R A Zimmerman
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

8.  Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children.

Authors:  P A Grabb; A L Albright; D Pang
Journal:  Neurosurgery       Date:  1992-01       Impact factor: 4.654

9.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

Authors:  J L Finlay; J M Boyett; A J Yates; J H Wisoff; J M Milstein; J R Geyer; S J Bertolone; P McGuire; J M Cherlow; M Tefft
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

10.  Leptomeningeal dissemination of primary central nervous system tumors of childhood.

Authors:  R J Packer; K R Siegel; L N Sutton; P Litmann; D A Bruce; L Schut
Journal:  Ann Neurol       Date:  1985-08       Impact factor: 10.422

View more
  18 in total

1.  Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma.

Authors:  A Broniscer; R G Tatevossian; N D Sabin; P Klimo; J Dalton; R Lee; A Gajjar; D W Ellison
Journal:  Neuropathol Appl Neurobiol       Date:  2014-04       Impact factor: 8.090

2.  Irradiation of pediatric high-grade spinal cord tumors.

Authors:  Rahul D Tendulkar; Atmaram S Pai Panandiker; Shengjie Wu; Larry E Kun; Alberto Broniscer; Robert A Sanford; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-24       Impact factor: 7.038

3.  Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.

Authors:  Rajni Sethi; Jeffrey Allen; Bernadine Donahue; Matthias Karajannis; Sharon Gardner; Jeffrey Wisoff; Saroj Kunnakkat; Jeena Mathew; David Zagzag; Kia Newman; Ashwatha Narayana
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

4.  Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.

Authors:  K Müller; A Schlamann; M Guckenberger; M Warmuth-Metz; A Glück; S Pietschmann; A Wawer; R-D Kortmann; C Kramm; A O von Bueren
Journal:  Strahlenther Onkol       Date:  2014-02-19       Impact factor: 3.621

Review 5.  Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?

Authors:  Darren Hargrave
Journal:  CNS Oncol       Date:  2012-11

6.  Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database.

Authors:  Birte Wolff; Ann Ng; Daniela Roth; Kathleen Parthey; Monika Warmuth-Metz; Matthias Eyrich; Uwe Kordes; Rolf Kortmann; Torsten Pietsch; Christof Kramm; Johannes Ea Wolff
Journal:  J Neurooncol       Date:  2011-10-01       Impact factor: 4.130

Review 7.  Advances in the management of paediatric high-grade glioma.

Authors:  Jenny Adamski; Uri Tabori; Eric Bouffet
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

8.  Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database.

Authors:  Johannes E A Wolff; Carl Friedrich Classen; Sabine Wagner; Rolf-Dieter Kortmann; Shana L Palla; Torsten Pietsch; Joachim Kühl; Astrid Gnekow; Christof M Kramm
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

9.  Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.

Authors:  Johannes E A Wolff; Christof Kramm; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski; Norbert Jorch; Astrid Gnekow; Pablo Hernáiz Driever
Journal:  J Neurooncol       Date:  2008-08-05       Impact factor: 4.130

10.  A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.

Authors:  Regina I Jakacki; Allan Yates; Susan M Blaney; Tianni Zhou; Robert Timmerman; Ashish M Ingle; Lynda Flom; Michael D Prados; Peter C Adamson; Ian F Pollack
Journal:  Neuro Oncol       Date:  2008-05-22       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.